Pharmacodynamics of the Adaptation of Drugs to Activity in Extreme Conditions

A decrease in a person’s physical and mental performance, which occurs during activity in difficult conditions, under extreme influences, determines the advisability of using drugs aimed at pathogenetically significant mechanisms and targets for the development of distress as means of pharmacological support for adaptation processes. The Research Institute of Pharmacology, over the course of many years, has accumulated significant experience in performing research and applied developments in order to improve the arsenal of medicines necessary for adaptation that are superior in effectiveness to existing ones. The review presents the developments of the original anxiolytic Afobazole, the nootropic drug Noopept, the antiasthenic drug Ladasten, and the drug Loxidan, an emergency means of increasing physical performance. Information is provided on the results of new exploratory pharmacological studies for the treatment of anxiety disorders, depression, and post-traumatic stress disorders, aimed at regulating the central mechanisms that determine the development of distress and emerging pathologies.